Skip to main content

Monoclonal Antibody Production (1999) / Chapter Skim
Currently Skimming:

Conclusions and Recommendations
Pages 45-47

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 45...
... When hybridomas fail to grow or fail to achieve a product consistent with scientific goals, the investigator is obliged to show that a good-faith effort was made to adapt the hybridoma to in vitro growth conditions before using the mouse ascites method. Recommendation 1: There is a need for the scientific community to avoid or minimize pain and suffering by the animals.
Read the entire page →
From page 46...
... There are several scientifically based reasons why the mouse ascites method for producing mAb should not be abandoned: some hybridoma cell lines do not adapt well to in vitro conditions; when small volumes of mouse mAb at high concentrations are required for injection into mice, the in vitro method often does not yield an acceptable product; rat hybridoma cell lines usually do not efficiently generate ascites in rats and adapt poorly to in vitro conditions but do produce mAb in immunocompromised mice; concentrating mAb from in vitro culture supernatant can lead to protein denaturation and decreased antibody activity; in vitro culture methods can yield mAb that do not reflect normal glycosylation patterns, in contrast with mAb generated by the mouse ascites method, and the lack of natural glycosylation might influence antigen-binding capacity and critical biologic functions; contamination of valuable in vitro clones with fungi or bacteria requires prompt passage through a mouse to save the cell line; and inability of in vitro-adapted cell lines to maintain adequate production of mAb poses a serious problem. Recommendation 2: The mouse ascites method of producing monoclonal antibodies should not be banned, because there is and will continue to be scientific necessity for this method.
Read the entire page →
From page 47...
... We emphasize that the listed criteria are not all-inclusive and that it is the responsibility of the IACUC to determine whether animal use is required for scientific or regulatory reasons. Criteria have not been developed to define a low-producing hybridoma cell line or when in vitro methods are no longer a useful means of producing mAb.
Read the entire page →

Key Terms

  • mouse ascites
  • cell lines
  • producing mab
  • hybridoma cell
  • vitro methods

  • vitro conditions
  • mab produced
  • fluid accumulation
  • cell line
  • vitro culture

  • monoclonal antibodies
  • hybridoma cells
  • commercially produced
  • significant ascites
  • scientifically based

  • ascites fluid
  • maintain adequate
  • mab generated
  • infectious agents
  • vitro growth

  • antibody activity
  • protein denaturation
  • decreased antibody
  • vitro clones
  • prompt passage

  • efficiently generate
  • vitro production
  • reflect normal
  • product consistent
  • critical biologic


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.